CMPS250117P15000
- 0.00
- 0.000.00%
COMPASS Pathways Newsroom
BTIG Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $17
Compass Pathways Is Maintained at Outperform by RBC Capital
Compass Pathways Analyst Ratings
Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Cuts Target Price to $12
A Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $12 to $23
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
Buy Rating Affirmed for COMPASS Pathways Amid Progress in Pivotal Trials and Strong Financial Position
CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $48
Buy Rating Affirmed: COMPASS Pathways' Promising Clinical Trials Advance Psychedelic Therapeutics
TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
TD Cowen Remains a Buy on COMPASS Pathways (CMPS)
Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $22
Oppenheimer Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $25
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
A Quick Look at Today's Ratings for COMPASS Pathways(CMPS.US), With a Forecast Between $23 to $48
Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
Compass Pathways Price Target Cut to $48.00/Share From $50.00 by Canaccord Genuity
Compass Pathways Analyst Ratings
Buy Rating Affirmed for COMPASS Pathways Amid Positive Clinical Trial Progress and Solid Financial Footing